Laboratory response to paradigm change in hemophilia treatment How to monitor patients simultaneously treated with emicizumab and factor VIII concentrate?

被引：0
作者：
Lambert, Marjan Shafaati [1 ,2 ]
Bruzelius, Maria [3 ,4 ]
Soutari, Nida Mahmoud Hourani [1 ,2 ]
Ranta, Susanna [5 ,6 ]
Antovic, Jovan P. P. [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Mol Med & Surg, Coagulat & Clin Chem, Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Univ Lab, Coagulat Clin Chem, Med Diagnost Karolinska, Stockholm, Sweden
[3] Karolinska Inst, Dept Med, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[5] Karolinska Univ Hosp, Astrid Lindgrens Childrens Hosp, Stockholm, Sweden
[6] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
来源：
CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2023年 / 61卷 / 12期
关键词：
emicizumab; FVIII concentrate; FVIII:C CSA;
D O I：
10.1515/cclm-2023-0443
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：E248 / E250
页数：3
相关论文
共 11 条
  • [1] The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer, Annette E.
    Maclean, Rhona M.
    Kitchen, Steve
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 (03) : 368 - 376
  • [2] Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro
    Bravo, Maria Isabel
    Raventos, Aida
    Perez, Alba
    Costa, Montserrat
    Willis, Todd
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (08) : 1934 - 1939
  • [3] The More Recent History of Hemophilia Treatment
    Franchini, Massimo
    Mannucci, Pier Mannuccio
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (08) : 904 - 910
  • [4] Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
    Mahlangu, Johnny N.
    [J]. BIODRUGS, 2018, 32 (06) : 561 - 570
  • [5] Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A
    Mueller, Jens
    Pekru, Isabell
    Poetzsch, Bernd
    Berning, Beate
    Oldenburg, Johannes
    Spannagl, Michael
    [J]. THROMBOSIS AND HAEMOSTASIS, 2019, 119 (09) : 1384 - 1393
  • [6] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Oldenburg, Johannes
    Mahlangu, Johnny N.
    Kim, Benjamin
    Schmitt, Christophe
    Callaghan, Michael U.
    Young, Guy
    Santagostino, Elena
    Kruse-Jarres, Rebecca
    Negrier, Claude
    Kessler, Craig
    Valente, Nancy
    Asikanius, Elina
    Levy, Gallia G.
    Windyga, Jerzy
    Shima, Midori
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) : 809 - 818
  • [7] Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays
    Peyvandi, Flora
    Kenet, Gili
    Pekrul, Isabell
    Pruthi, Rajiv K.
    Ramge, Peter
    Spannagl, Michael
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (06) : 1242 - 1255
  • [8] Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
    Pipe, Steven W.
    Shima, Midori
    Lehle, Michaela
    Shapiro, Amy
    Chebon, Sammy
    Fukutake, Katsuyuki
    Key, Nigel S.
    Portron, Agnes
    Schmitt, Christophe
    Podolak-Dawidziak, Maria
    Bienz, Nives Selak
    Hermans, Cedric
    Campinha-Bacote, Avrita
    Kiialainen, Anna
    Peerlinck, Kathelijne
    Levy, Gallia G.
    Jimenez-Yuste, Victor
    [J]. LANCET HAEMATOLOGY, 2019, 6 (06): : E295 - E305
  • [9] Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
    Schmitt, Christophe
    Adamkewicz, Joanne I.
    Xu, Jin
    Petry, Claire
    Catalani, Olivier
    Young, Guy
    Negrier, Claude
    Callaghan, Michael U.
    Levy, Gallia G.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2021, 121 (03) : 351 - 360
  • [10] Sjöström A, 2020, HAEMOPHILIA, V26, P28
12